Abstract: The present disclosure relates to methods and systems for automatically providing a suggestion to delay sending a message that is being composed by a user to send to a chat participant using a chat feature of an application. The suggestion is sent in response to determining that one or more trigger conditions occurred. The suggestion includes a scheduled time to send the message. The methods and systems send the delayed message at the scheduled time.

Abstract: A headgear assembly for retaining a respiratory mask on a user's face includes arrangements or components that allow for variation in a size of the headgear assembly. In some configurations, the headgear assembly includes one or more hubs, each of which are configured to connect a top and rear strap together. The size of the headgear assembly can be determined by the size or configuration of the hub. In other configurations, the headgear assembly comprises one or more spacer elements within one or more straps of the headgear. The size of the headgear assembly can be determined by the size of the spacer element or a relative position between the strap and the spacer element.

Abstract: An interface and headgear assembly includes a headgear assembly. The headgear assembly has a first strap configured to connect to the interface. A crown strap can be adjusted along a length of the first strap. In some configurations, the crown strap has a first portion and a second portion that are adjustably connected. The crown strap can be removably connected to the first strap using bridge regions of the first portion and the second portion.

Abstract: The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

Abstract: The present invention relates in general to compositions and methods for treating an animal or human patient in need of treatment for ophthalmic diseases or conditions involving oxidative stress and treatment with an ophthalmic implant containing (2R,2R?)-3,3?-disulfanediyl bis(2-cetamidopropanamide) (diNACA), wherein such ophthalmic diseases or conditions include but not limited to cataracts, cataracts in a subject that does not have diabetes, corneal endothelial cell loss, age-related macular degeneration, presbyopia, retinitis pigmentosa (RP), Usher syndrome, Stargardt syndrome, glaucoma, diabetic retinopathy, and/or retinal disease.

Abstract: A headgear assembly for retaining a respiratory mask on a user's face includes arrangements or components that allow for variation in a size of the headgear assembly. In some configurations, the headgear assembly includes one or more hubs, each of which are configured to connect a top and rear strap together. The size of the headgear assembly can be determined by the size or configuration of the hub. In other configurations, the headgear assembly comprises one or more spacer elements within one or more straps of the headgear. The size of the headgear assembly can be determined by the size of the spacer element or a relative position between the strap and the spacer element.

Abstract: The present invention includes a method for the treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to treat or reduce the symptoms of the age-related macular degeneration, glaucoma, or diabetic retinopathy.

Abstract: The present invention includes pharmaceutical composition comprising (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA), deuterated NACA-d3, deuterated di-NACA-d6, combinations thereof, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA, NACA-d3, di-NACA-d6, or combinations thereof, to treat eye diseases and other diseases associated with oxidative damage including, e.g.

Abstract: A headgear portion or assembly for use in combination with a breathing apparatus in some configurations is at least substantially inelastic and is three dimensional in shape. The headgear portion or assembly can comprise a plastic core and a textile casing. The headgear, or part thereof, may also have integrally moulded labels, connectors, adjustment mechanisms and/or grips.

Abstract: The apparatus, method, and system disclosed relates to a headgear assembly for a respiratory system for the delivery of respiratory therapy to a patient. The headgear comprises a yoke at least partially formed from an elastomeric material. The yoke is configured to be stretched under tension to attach the yoke to the headgear assembly.

Abstract: An interface and headgear assembly includes a headgear assembly. The headgear assembly has a first strap configured to connect to the interface. A crown strap can be adjusted along a length of the first strap. In some configurations, the crown strap has a first portion and a second portion that are adjustably connected. The crown strap can be removably connected to the first strap using bridge regions of the first portion and the second portion.

Abstract: The present invention includes a method for the treatment of age-related macular degeneration, glaucoma, or diabetic retinopathy in a human that comprises administering to the human a therapeutically effective amount of N-acetylcysteine amide (NACA) or (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide) (diNACA) sufficient to treat or reduce the symptoms of the age-related macular degeneration, glaucoma, or diabetic retinopathy.

Abstract: The present invention includes pharmaceutical composition comprising (2R,2R?)-3,3?-disulfanediyl bis(2-acetamidopropanamide)(diNACA) or D3-N-acetyl cysteine amide, or a physiologically acceptable salt thereof, having a deuterium enrichment above the natural abundance of deuterium, and derivatives or solids thereof, and methods of using diNACA to treat eye diseases and other diseases associated with oxidative damage including, e.g., antivenom, beta-thallassemia, cataract, chronic obstructive pulmonary disease, macular degeneration, contrast-induced nephropathy, asthma, lung contusion, methamphetamine-induced oxidative stress, multiple sclerosis, Parkinson's disease, platelet apoptosis, Tardive dyskinesia, Alzheimer disease, HIV-1-associated dementia, mitochondrial diseases, myocardial myopathy, neurodegenerative diseases, pulmonary fibrosis, skin pigmentation, skin in need of rejuventation, antimicrobial infection, Friedreich's ataxia.

Abstract: The apparatus, method, and system disclosed relates to a headgear assembly for a respiratory system for the delivery of respiratory therapy to a patient. The headgear comprises a yoke at least partially formed from an elastomeric material. The yoke is configured to be stretched under tension to attach the yoke to the headgear assembly.